reports
Edison issues review on Tetragon Financial Group (TFG): FY23 growth dr...
Edison Investment Research Limited Edison issues review on Tetragon Financial Group (TFG): FY23 growth driven by idiosyncratic factors 16-Apr-2024 / 12:07 GMT/BST The issuer is solely responsible for the content of this announcement. London, UK, 16 April 2024 Edison issues review on Tetragon Financial Group (TFG): FY23 growth driven by idiosyncratic factors Tetragon Financial Group (Tetragon) posted a 6.4% net asset value (NAV) per share total return in US dollar terms in FY23. Tetragon’s returns normally have a low correlation with broader markets, and therefore its FY23 pe...
Divfex Berhad: 1 director
A director at Divfex Berhad sold 4,870,000 shares at 0.133MYR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
KRM22: 1 director
A director at KRM22 bought 100,000 shares at 25p and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Clos...
Zhongzhi Pharmaceutical Holdings Limited: 1 director
A director at Zhongzhi Pharmaceutical Holdings Limited bought 2,259,000 shares at 1.170HKD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony...
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors - Appointment Adds Broad Expertise in Business Strategy, Collaborations, Finance, and M&A with Recent Ophthalmic Experience - ALPHARETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Anthony S. Gibney has been appointed to the Company's Board of Directors, effective April 15, 2024. “We are...
EQS-News: CureVac and MD Anderson Enter Strategic Collaboration to De...
Issuer: CureVac / Key word(s): Alliance CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines 16.04.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines Agreement creates strong synergies between CureVac’s unique end-to-end mRNA capabilities and MD Anderson’s translational and clinical research expertise Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematologic...
EQS-News: CureVac und MD Anderson gehen strategische Kooperation zur E...
Emittent / Herausgeber: CureVac / Schlagwort(e): Kooperation CureVac und MD Anderson gehen strategische Kooperation zur Entwicklung neuartiger Krebsimpfstoffe ein 16.04.2024 / 13:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. CureVac und MD Anderson gehen strategische Kooperation zur Entwicklung neuartiger Krebsimpfstoffe ein Kooperation schafft starke Synergien zwischen einzigartiger mRNA-Kompetenz von CureVac und translationaler und klinischer Forschungsexpertise von MD Anderson Entwicklung neuartiger, „off-the-shelf“ ...
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results fr...
Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints Lumateperone 42 mg met the primary endpoint of change from baseline at Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score versus placebo (4.9 point reduction v. placebo; p
Melco International Development: 1 director
A director at Melco International Development bought 1,200,000 shares at 5.700HKD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
Thanh Thanh Cong - Bien Hoa : 1 director
A director at Thanh Thanh Cong - Bien Hoa sold 15,000,000 shares at 0.000VND and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
Hanwha Life Insurance Co Ltd: 1 director
A director at Hanwha Life Insurance Co Ltd bought 20,000 shares at 2,640.000KRW and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
Fiera Capital Corp: 1 director
A director at Fiera Capital Corp sold 61,600 shares at 7.800CAD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Nam Song Hau Trading Investing Petroleum Joint Stock Company: 1 direct...
A director at Nam Song Hau Trading Investing Petroleum Joint Stock Company sold 2,017,700 shares at 0.000VND and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the comp...
Voyager Therapeutics Announces Selection of Development Candidate for ...
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment LEXINGTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson’s disease and other GBA1-mediated diseases. The candidate c...
Treace Announces First Annual National Bunion Day
Treace Announces First Annual National Bunion Day Focus on Foot Health Issue Affecting Millions of People Includes Outreach and Education Efforts to Build Awareness, Reduce Stigma and Correct Misconceptions About This Common Bone Deformity PONTE VEDRA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship and Procedures, today announced the first-ever National Bunion Day in the ...
Aya Or & Argent annonce une robuste estimation de ressources minérales...
Aya Or & Argent annonce une robuste estimation de ressources minérales à Boumadine MONTRÉAL, 16 avr. 2024 (GLOBE NEWSWIRE) -- Aya Or & Argent Inc. (TSX : AYA; OTCQX : AYASF) (« Aya » ou la « Société ») a le plaisir d’annoncer une estimation de ressources minérales (« ERM ») préparée conformément au Règlement 43-101 sur l’information concernant les projets miniers (le « Règlement 43-101 ») sur son projet Boumadine dans le Royaume du Maroc. L’ERM fait état de ressources minérales présumées de 23,6 millions de tonnes (« Mt ») à 85 grammes par tonne (« g/t ») d’argent (« Ag »), 2,62 g/t d’or ...
Multitude SE - Managers' transactions - Vella
Multitude SE - Managers' transactions - Vella Multitude SE - Managers' transactions - Vella ____________________________________________ Person subject to the notification requirementName: Vella, ShaunPosition: Other senior managerIssuer: Multitude SELEI: 74370078YLPFWHE33716 Notification type: INITIAL NOTIFICATIONReference number: 74370078YLPFWHE33716_20240416104440_137____________________________________________ Transaction date: 2024-04-15Venue not applicableInstrument type: SHAREISIN: FI4000106299Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction deta...
OptimizeRx Reports Strong Fourth Quarter and Full Year 2023 Financial ...
OptimizeRx Reports Strong Fourth Quarter and Full Year 2023 Financial Results Q4 revenue of $28.4 million, increasing 44% year-over-yearQ4 gross profit increased 43% year-over-year to $17.8 million with gross margins coming in at 63% for both periodsAcquired Healthy Offers, Inc. (dba Medicx Health), a leading healthcare consumer-focused omnichannel marketing and analytics company that significantly expands our footprint with consumers and patientsMeaningfully increased our DAAP footprint: 24 DAAP deals in 2023 compared to six deals in 2022 WALTHAM, Mass., April 16, 2024 (GLOBE NE...
Foghorn Therapeutics Strengthens Financial Leadership with Appointment...
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer CAMBRIDGE, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that Kristian Humer will join the company as Chief Financial Officer (CFO) on April 16, 2024. Mr. Humer joins Foghorn with over 14 years of diversified financial strategy and business development experience in the life scien...
Beneficient Announces Reverse Stock Split to Regain Compliance with Na...
Beneficient Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price DALLAS, April 16, 2024 (GLOBE NEWSWIRE) -- Beneficient (Nasdaq: BENF), a technology-enabled platform providing liquidity and related trust and custody services to holders of alternative assets through its proprietary online platform, AltAccess, today announced a 1-for-80 reverse stock split (the “Reverse Stock Split”) of its Class A common stock, par value $0.001 per share (the “Class A Common Stock”), and its Class B common stock, par value $0.001 per share (“Class B Common Stock” and together ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.